Because of in vitro studies, hydroxychloroquine has been evaluated as a preexposure or postexposure prophylaxis for coronavirus disease (COVID-19) and as a possible COVID-19 curative treatment. We report a case of COVID-19 in a patient with sarcoidosis who was receiving long-term hydroxychloroquine treatment and contracted COVID-19 despite adequate plasma concentrations.
Keywords: 2019 novel coronavirus disease; COVID-19; France; SARS-CoV-2; coronavirus; coronavirus disease; hydroxychloroquine; plasma concentration; respiratory infections; sarcoidosis; severe acute respiratory syndrome coronavirus 2; viruses; zoonoses.